{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:09:49Z","timestamp":1789027789460,"version":"build-2803163510"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Key Industrial Innovation Chain Project in Shaanxi Province of China","award":["(2023-ZDLSF-21"],"award-info":[{"award-number":["(2023-ZDLSF-21"]}]},{"name":"Shaanxi Association for Science and Technology","award":["2026swyy17"],"award-info":[{"award-number":["2026swyy17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05895-5","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:40:35Z","timestamp":1789022435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-database pharmacovigilance identifies disproportionate reporting of hepatobiliary events with avacopan: an integrative study with network pharmacology and interpretable machine learning"],"prefix":"10.1007","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"5895_CR1","doi-asserted-by":"crossref","unstructured":"(2024) Avacopan for antineutrophil cytoplasmic antibody\u2013associated vasculitis [J]. Aust Prescr 47(5):158\u20139","DOI":"10.18773\/austprescr.2024.038"},{"issue":"9","key":"5895_CR2","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1177\/0960327113512860","volume":"33","author":"DE Amacher","year":"2014","unstructured":"Amacher DE (2014) Female gender as a susceptibility factor for drug-induced liver injury [J]. Hum Exp Toxicol 33(9):928\u2013939","journal-title":"Hum Exp Toxicol"},{"issue":"1","key":"5895_CR3","first-page":"854015","volume":"2015","author":"L Basheer","year":"2015","unstructured":"Basheer L, Kerem Z (2015) Interactions between CYP3A4 and dietary polyphenols [J]. Oxid Med Cell Longev 2015(1):854015","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"5895_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR et al (1998) A Bayesian neural network method for adverse drug reaction signal generation [J]. Eur J Clin Pharmacol 54(4):315\u2013321","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"5895_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting [J]. Pharmacoepidemiol Drug Saf 18(6):427\u2013436","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"21","key":"5895_CR6","doi-asserted-by":"publisher","first-page":"11716","DOI":"10.1021\/acs.jcim.5c02015","volume":"65","author":"L Bernal","year":"2025","unstructured":"Bernal L, Rastelli G, Pinzi L (2025) Improving machine learning classification predictions through SHAP and features analysis interpretation [J]. J Chem Inf Model 65(21):11716\u201311732","journal-title":"J Chem Inf Model"},{"issue":"5","key":"5895_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40264-015-0281-0","volume":"38","author":"JC Bouvy","year":"2015","unstructured":"Bouvy JC, de Bruin ML, Koopmanschap MA (2015) Epidemiology of adverse drug reactions in Europe: a review of recent observational studies [J]. Drug Saf 38(5):437\u2013453","journal-title":"Drug Saf"},{"issue":"8","key":"5895_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","volume":"27","author":"EG Brown","year":"2004","unstructured":"Brown EG (2004) Using MedDRA: implications for risk management [J]. Drug Saf 27(8):591\u2013602","journal-title":"Drug Saf"},{"key":"5895_CR9","doi-asserted-by":"crossref","unstructured":"Chalasani NP, Hayashi PH, Bonkovsky HL et al (2014) ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury [J]. Am J Gastroenterol 109(7):950\u201366; quiz 67","DOI":"10.1038\/ajg.2014.131"},{"issue":"7","key":"5895_CR10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R et al (2015) Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study [J]. Gastroenterology 148(7):1340\u201352.e7","journal-title":"Gastroenterology"},{"key":"5895_CR11","doi-asserted-by":"crossref","unstructured":"Catherinot E, Lanternier F, Bougnoux M-E et al (2010) <em>Pneumocystis jirovecii<\/em> Pneumonia [J]. Infect Dis Clin 24(1):107\u201338","DOI":"10.1016\/j.idc.2009.10.010"},{"issue":"9","key":"5895_CR12","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/ndt\/gfae020","volume":"39","author":"A Chalkia","year":"2024","unstructured":"Chalkia A, Flossmann O, Jones R et al (2024) Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage [J]. Nephrol Dial Transplant 39(9):1473\u20131482","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"5895_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12933-024-02538-y","volume":"23","author":"Y Chen","year":"2024","unstructured":"Chen Y, Yang Z, Liu Y et al (2024) Exploring the prognostic impact of triglyceride-glucose index in critically ill patients with first-ever stroke: insights from traditional methods and machine learning-based mortality prediction [J]. Cardiovasc Diabetol 23(1):443","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"5895_CR14","doi-asserted-by":"publisher","first-page":"18063","DOI":"10.1038\/s41598-025-01206-9","volume":"15","author":"H Chen","year":"2025","unstructured":"Chen H, Liu S, Gao S et al (2025) Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System [J]. Sci Rep 15(1):18063","journal-title":"Sci Rep"},{"issue":"8","key":"5895_CR15","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M et al (2021) 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis [J]. Arthritis Rheumatol 73(8):1366\u20131383","journal-title":"Arthritis Rheumatol"},{"issue":"W1","key":"5895_CR16","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina A, Michielin O, Zoete V (2019) SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules [J]. Nucleic Acids Res 47(W1):W357\u2013W364","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"5895_CR17","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1016\/j.cell.2023.04.031","volume":"186","author":"JV Desai","year":"2023","unstructured":"Desai JV, Kumar D, Freiwald T et al (2023) C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection [J]. Cell 186(13):2802\u201322.e22","journal-title":"Cell"},{"issue":"3","key":"5895_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2174\/1574886310666150729112903","volume":"10","author":"P Dias","year":"2015","unstructured":"Dias P, Penedones A, Alves C et al (2015) The role of disproportionality analysis of pharmacovigilance databases in safety regulatory actions: a systematic review [J]. Curr Drug Saf 10(3):234\u2013250","journal-title":"Curr Drug Saf"},{"issue":"4","key":"5895_CR19","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.apsb.2025.02.017","volume":"15","author":"C Ding","year":"2025","unstructured":"Ding C, Wang Z, Shi K et al (2025) Taxifolin attenuates liver fibrosis by regulating the phosphorylation of NDRG1 at Thr328 via hepatocyte-stellate cell cross talk [J]. Acta Pharm Sin B 15(4):2059\u20132076","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"5895_CR20","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","volume":"105","author":"J Floege","year":"2024","unstructured":"Floege J, Jayne DR, Sanders JS, Tesar V, Rovin BH (2024) KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)\u2013associated vasculitis. Kidney Int 105(3):S71-116","journal-title":"Kidney Int"},{"issue":"6","key":"5895_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement [J]. Drug Saf 47(6):575\u2013584","journal-title":"Drug Saf"},{"issue":"2","key":"5895_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40264-025-01604-y","volume":"49","author":"M Fusaroli","year":"2026","unstructured":"Fusaroli M, Sartori D, van Puijenbroek EP et al (2026) Charting and sidestepping the pitfalls of disproportionality analysis [J]. Drug Saf 49(2):147\u2013162","journal-title":"Drug Saf"},{"issue":"W1","key":"5895_CR23","doi-asserted-by":"publisher","first-page":"W726","DOI":"10.1093\/nar\/gkac297","volume":"50","author":"K Gallo","year":"2022","unstructured":"Gallo K, Goede A, Preissner R et al (2022) SuperPred 3.0: drug classification and target prediction-a machine learning approach [J]. Nucleic Acids Res 50(W1):W726-w31","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"5895_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/2047487320915663","volume":"28","author":"M Gatti","year":"2021","unstructured":"Gatti M, Antonazzo IC, Diemberger I et al (2021) Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system [J]. Eur J Prev Cardiol 28(9):983\u2013989","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"5895_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/ard-2023-224816","volume":"83","author":"D Geetha","year":"2024","unstructured":"Geetha D, Dua A, Yue H et al (2024) Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial [J]. Ann Rheum Dis 83(2):223\u2013232","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5895_CR26","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1093\/rheumatology\/keaf122","volume":"64","author":"D Geetha","year":"2025","unstructured":"Geetha D, Pagnoux C, Sattui SE et al (2025) Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial [J]. Rheumatology (Oxford) 64(6):3863\u20133871","journal-title":"Rheumatology (Oxford)"},{"key":"5895_CR27","doi-asserted-by":"publisher","first-page":"113202","DOI":"10.1016\/j.biopha.2022.113202","volume":"152","author":"Y Gloor","year":"2022","unstructured":"Gloor Y, Lloret-Linares C, Bosilkovska M et al (2022) Drug metabolic enzyme genotype-phenotype discrepancy: High phenoconversion rate in patients treated with antidepressants [J]. Biomed Pharmacother 152:113202","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5895_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH et al (2024) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update [J]. Ann Rheum Dis 83(1):30\u201347","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5895_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s43441-024-00729-z","volume":"59","author":"S Ito","year":"2025","unstructured":"Ito S, Narukawa M (2025) Development of a drug safety signal detection reference set using Japanese safety information [J]. Ther Innov Regul Sci 59(2):288\u2013294","journal-title":"Ther Innov Regul Sci"},{"key":"5895_CR30","unstructured":"Janzing D, Minorics L, Bloebaum P (2020) Feature relevance quantification in explainable AI: A causal problem [Z]\/\/SILVIA C, ROBERTO C. Proceedings of the Twenty Third International Conference on Artificial Intelligence and Statistics. Proceedings of Machine Learning Research; PMLR, 2907\u2013\u201316"},{"issue":"9","key":"5895_CR31","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"Jayne DRW, Bruchfeld AN, Harper L et al (2017) Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis [J]. J Am Soc Nephrol 28(9):2756\u20132767","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"5895_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ et al (2021) Avacopan for the treatment of ANCA-associated vasculitis [J]. N Engl J Med 384(7):599\u2013609","journal-title":"N Engl J Med"},{"issue":"2","key":"5895_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/mrcr\/rxad019","volume":"7","author":"H Kataoka","year":"2023","unstructured":"Kataoka H, Tomita T, Nakanowatari M et al (2023) Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis [J]. Mod Rheumatol Case Rep 7(2):444\u2013447","journal-title":"Mod Rheumatol Case Rep"},{"issue":"11","key":"5895_CR34","doi-asserted-by":"publisher","first-page":"e15400","DOI":"10.1111\/1756-185X.15400","volume":"27","author":"Y Kioi","year":"2024","unstructured":"Kioi Y, Itotagawa E, Kawachi Y et al (2024) Case report: Avacopan-induced severe liver injury with prolonged jaundice and lipoprotein X-induced dyslipidemia [J]. Int J Rheum Dis 27(11):e15400","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"5895_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","volume":"6","author":"AR Kitching","year":"2020","unstructured":"Kitching AR, Anders HJ, Basu N et al (2020) ANCA-associated vasculitis [J]. Nat Rev Dis Primers 6(1):71","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"5895_CR36","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1093\/rheumatology\/kead509","volume":"63","author":"K Kojima","year":"2024","unstructured":"Kojima K, Fukui S, Tanigawa M et al (2024) Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan [J]. Rheumatology (Oxford) 63(3):e101\u2013e103","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"5895_CR37","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1124\/dmd.120.000261","volume":"49","author":"M Kumondai","year":"2021","unstructured":"Kumondai M, GUTI\u00e9RREZ RICO EM, Hishinuma E et al (2021) Functional characterization of 40 CYP3A4 variants by assessing midazolam 1\u2019-hydroxylation and testosterone 6\u03b2-hydroxylation. Drug Metab Dispos 49(3):212\u2013220","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"5895_CR38","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/hep.23317","volume":"51","author":"C Lammert","year":"2010","unstructured":"Lammert C, Bjornsson E, Niklasson A et al (2010) Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events [J]. Hepatology 51(2):615\u2013620","journal-title":"Hepatology"},{"issue":"6","key":"5895_CR39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/14740338.2023.2243220","volume":"23","author":"Z Li","year":"2024","unstructured":"Li Z, Zou W, Yuan J et al (2024) Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system [J]. Expert Opin Drug Saf 23(6):763\u2013770","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"5895_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41746-025-02173-1","volume":"9","author":"L Li","year":"2026","unstructured":"Li L, Jing S, Zhao X et al (2026) Computational pharmacovigilance of Lifitegrast in dry eye disease using machine learning and network toxicology [J]. NPJ Digit Med 9(1):30","journal-title":"NPJ Digit Med"},{"key":"5895_CR41","doi-asserted-by":"publisher","first-page":"109895","DOI":"10.1016\/j.biopha.2020.109895","volume":"125","author":"B Liu","year":"2020","unstructured":"Liu B, Deng X, Jiang Q et al (2020) Scoparone improves hepatic inflammation and autophagy in mice with nonalcoholic steatohepatitis by regulating the ROS\/P38\/Nrf2 axis and PI3K\/AKT\/mTOR pathway in macrophages [J]. Biomed Pharmacother 125:109895","journal-title":"Biomed Pharmacother"},{"issue":"W1","key":"5895_CR42","doi-asserted-by":"publisher","first-page":"W159","DOI":"10.1093\/nar\/gkac394","volume":"50","author":"Y Liu","year":"2022","unstructured":"Liu Y, Yang X, Gan J et al (2022) CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting [J]. Nucleic Acids Res 50(W1):W159\u2013W164","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"5895_CR43","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1007\/s00787-025-02694-w","volume":"34","author":"J Liu","year":"2025","unstructured":"Liu J, Xue L, Zeng F et al (2025) Exploring the potential association between stimulant or atomoxetine use and suicidal or self-injurious behaviors in children with attention deficit hyperactivity disorder: real-world insights from the FAERS database [J]. Eur Child Adolesc Psychiatry 34(8):2585\u20132597","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"6","key":"5895_CR44","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","volume":"152","author":"R Loomba","year":"2017","unstructured":"Loomba R, Liang TJ (2017) Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions [J]. Gastroenterology 152(6):1297\u20131309","journal-title":"Gastroenterology"},{"key":"5895_CR45","unstructured":"Lundberg SM, Lee S-I (2017) A unified approach to interpreting model predictions [Z]. Proceedings of the 31st International Conference on Neural Information Processing Systems. Long Beach, California, USA; Curran Associates Inc, 4768\u201377"},{"issue":"21","key":"5895_CR46","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1016\/j.jmb.2013.07.010","volume":"425","author":"VY Martiny","year":"2013","unstructured":"Martiny VY, Miteva MA (2013) Advances in molecular modeling of human cytochrome P450 polymorphism [J]. J Mol Biol 425(21):3978\u20133992","journal-title":"J Mol Biol"},{"issue":"9","key":"5895_CR47","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1093\/jac\/dkw158","volume":"71","author":"G Maschmeyer","year":"2016","unstructured":"Maschmeyer G, Helweg-Larsen J, Pagano L et al (2016) ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients [J]. J Antimicrob Chemother 71(9):2405\u20132413","journal-title":"J Antimicrob Chemother"},{"issue":"21","key":"5895_CR48","volume":"384","author":"Y Matsuo","year":"2021","unstructured":"Matsuo Y, Miyabe Y (2021) Avacopan for the treatment of ANCA-associated vasculitis [J]. N Engl J Med 384(21):e81","journal-title":"N Engl J Med"},{"issue":"6","key":"5895_CR49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.cpr.2009.05.003","volume":"29","author":"CP McLean","year":"2009","unstructured":"McLean CP, Anderson ER (2009) Brave men and timid women? A review of the gender differences in fear and anxiety [J]. Clin Psychol Rev 29(6):496\u2013505","journal-title":"Clin Psychol Rev"},{"issue":"2","key":"5895_CR50","first-page":"455","volume":"59","author":"CS Melincovici","year":"2018","unstructured":"Melincovici CS, Bo\u015fca AB, \u015eu\u015fman S et al (2018) Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis [J]. Rom J Morphol Embryol 59(2):455\u2013467","journal-title":"Rom J Morphol Embryol"},{"issue":"11","key":"5895_CR51","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/acr2.11185","volume":"2","author":"PA Merkel","year":"2020","unstructured":"Merkel PA, Niles J, Jimenez R et al (2020) Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis [J]. ACR Open Rheumatol 2(11):662\u2013671","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"5895_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70001","volume":"7","author":"PA Merkel","year":"2025","unstructured":"Merkel PA, George MD, Yue H et al (2025) Safety of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: combined data from three clinical trials [J]. ACR Open Rheumatol 7(4):e70001","journal-title":"ACR Open Rheumatol"},{"issue":"9","key":"5895_CR53","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/cpdd.1436","volume":"13","author":"S Miao","year":"2024","unstructured":"Miao S, Bekker P, Armas D et al (2024) Food effect and pharmacokinetic bridging of avacopan in Caucasian and Japanese healthy participants. Clin Pharmacol Drug Dev 13(9):1011\u20131023","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"5895_CR54","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/cpdd.1389","volume":"13","author":"S Miao","year":"2024","unstructured":"Miao S, Bekker P, Armas D et al (2024) Pharmacokinetic evaluation of the CYP3A4 and CYP2C9 drug-drug interaction of Avacopan in 2 open-label studies in healthy participants. Clin Pharmacol Drug Dev 13(5):517\u2013533","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"5895_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13878","volume":"17","author":"S Miao","year":"2024","unstructured":"Miao S, Staehr P, Tai E et al (2024) A phase I thorough QT\/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participants [J]. Clin Transl Sci 17(7):e13878","journal-title":"Clin Transl Sci"},{"issue":"2","key":"5895_CR56","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/rheumatology\/keaa215","volume":"60","author":"S Monti","year":"2021","unstructured":"Monti S, Craven A, Klersy C et al (2021) Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes [J]. Rheumatology (Oxford) 60(2):617\u2013628","journal-title":"Rheumatology (Oxford)"},{"key":"5895_CR57","doi-asserted-by":"publisher","first-page":"152048","DOI":"10.1016\/j.semarthrit.2022.152048","volume":"56","author":"S Monti","year":"2022","unstructured":"Monti S, Delvino P, Klersy C et al (2022) Factors influencing patient-reported outcomes in ANCA-associated vasculitis: correlates of the patient global assessment [J]. Semin Arthritis Rheum 56:152048","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"5895_CR58","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1093\/rheumatology\/keae689","volume":"64","author":"K Mori","year":"2025","unstructured":"Mori K, Shirai T, Mutoh T et al (2025) Drug-induced liver injury related to avacopan therapy. Rheumatology (Oxford) 64(5):2533\u20132540","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5895_CR59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","volume":"15","author":"D Nakazawa","year":"2019","unstructured":"Nakazawa D, Masuda S, Tomaru U et al (2019) Pathogenesis and therapeutic interventions for ANCA-associated vasculitis [J]. Nat Rev Rheumatol 15(2):91\u2013101","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"5895_CR60","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1007\/s00467-024-06376-8","volume":"39","author":"T Nishino","year":"2024","unstructured":"Nishino T, Tomori S, Haruyama M et al (2024) A case of rapid avacopan-induced liver injury in pediatric granulomatosis with polyangiitis [J]. Pediatr Nephrol 39(10):2919\u20132922","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"5895_CR61","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/ph14070681","volume":"14","author":"M Okunaka","year":"2021","unstructured":"Okunaka M, Kano D, Matsui R et al (2021) Comprehensive analysis of chemotherapeutic agents that induce infectious neutropenia [J]. Pharmaceuticals (Basel) 14(7):681","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"5895_CR62","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","volume":"4","author":"Y Oshima","year":"2018","unstructured":"Oshima Y, Tanimoto T, Yuji K et al (2018) EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer [J]. JAMA Oncol 4(8):1112\u20131115","journal-title":"JAMA Oncol"},{"key":"5895_CR63","doi-asserted-by":"publisher","first-page":"1463657","DOI":"10.3389\/fphar.2024.1463657","volume":"15","author":"Y Ou","year":"2024","unstructured":"Ou Y, Cui Z, Lou S et al (2024) Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups [J]. Front Pharmacol 15:1463657","journal-title":"Front Pharmacol"},{"key":"5895_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105147","volume":"81","author":"V Pang","year":"2024","unstructured":"Pang V, Seery N, Wesselingh R et al (2024) Neutropaenia complications from Ocrelizumab and Rituximab treatment [J]. Mult Scler Relat Disord 81:105147","journal-title":"Mult Scler Relat Disord"},{"key":"5895_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184331","author":"L Pinzi","year":"2019","unstructured":"Pinzi L, Rastelli G (2019) Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20184331","journal-title":"Int J Mol Sci"},{"issue":"8","key":"5895_CR66","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio [J]. Pharmacoepidemiol Drug Saf 13(8):519\u2013523","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5895_CR67","first-page":"baq020","volume":"201","author":"M Safran","year":"2010","unstructured":"Safran M, Dalah I, Alexander J et al (2010) GeneCards Version 3: the human gene integrator [J]. Database (Oxford) 201:baq020","journal-title":"Database (Oxford)"},{"key":"5895_CR68","doi-asserted-by":"publisher","first-page":"735260","DOI":"10.3389\/fphar.2021.735260","volume":"12","author":"Q Shao","year":"2021","unstructured":"Shao Q, Mao X, Zhou Z et al (2021) Research progress of pharmacogenomics in drug-induced liver injury [J]. Front Pharmacol 12:735260","journal-title":"Front Pharmacol"},{"issue":"9","key":"5895_CR69","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10654-020-00703-7","volume":"36","author":"M Shimonovich","year":"2021","unstructured":"Shimonovich M, Pearce A, Thomson H et al (2021) Assessing causality in epidemiology: revisiting Bradford Hill to incorporate developments in causal thinking [J]. Eur J Epidemiol 36(9):873\u2013887","journal-title":"Eur J Epidemiol"},{"key":"5895_CR70","doi-asserted-by":"crossref","unstructured":"Skat-R\u00f8rdam J, Lykkesfeldt J, Gluud LL et al (2025) Mechanisms of drug induced liver injury [J]. Cell Mol Life Sci 82(1):213.","DOI":"10.1007\/s00018-025-05744-3"},{"issue":"7","key":"5895_CR71","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/ard-2022-223559","volume":"82","author":"RM Smith","year":"2023","unstructured":"Smith RM, Jones RB, Specks U et al (2023) Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial [J]. Ann Rheum Dis 82(7):937\u2013944","journal-title":"Ann Rheum Dis"},{"key":"5895_CR72","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/10600280211030270","volume":"56","author":"K Takeda","year":"2021","unstructured":"Takeda K, Kobayashi C, Nakai T et al (2021) Analysis of the frequency and onset time of hyponatremia\/syndrome of inappropriate antidiuretic hormone induced by antidepressants or antipsychotics [J]. Ann Pharmacother 56:303\u2013308","journal-title":"Ann Pharmacother"},{"issue":"5","key":"5895_CR73","doi-asserted-by":"publisher","first-page":"e20305","DOI":"10.1371\/journal.pone.0020305","volume":"6","author":"J Tan","year":"2011","unstructured":"Tan J, Ma Z, Gao X et al (2011) Gender difference of unconscious attentional bias in high trait anxiety individuals [J]. PLoS ONE 6(5):e20305","journal-title":"PLoS ONE"},{"issue":"10","key":"5895_CR74","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1074\/jbc.M116.773085","volume":"292","author":"LY Tang","year":"2017","unstructured":"Tang LY, Heller M, Meng Z et al (2017) Transforming growth factor-\u03b2 (TGF-\u03b2) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway [J]. J Biol Chem 292(10):4302\u20134312","journal-title":"J Biol Chem"},{"key":"5895_CR75","doi-asserted-by":"publisher","first-page":"1463560","DOI":"10.3389\/fphar.2024.1463560","volume":"15","author":"H Tang","year":"2024","unstructured":"Tang H, Xu J, Zhang X et al (2024) A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1) [J]. Front Pharmacol 15:1463560","journal-title":"Front Pharmacol"},{"issue":"1","key":"5895_CR76","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41927-025-00456-4","volume":"9","author":"G Tagami","year":"2025","unstructured":"Tagami G, Yamaguchi M, Sugiyama H et al (2025) Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan [J]. BMC Rheumatol 9(1):8","journal-title":"BMC Rheumatol"},{"issue":"1","key":"5895_CR77","doi-asserted-by":"publisher","first-page":"18175","DOI":"10.1038\/s41598-025-03192-4","volume":"15","author":"Y Wan","year":"2025","unstructured":"Wan Y, Zhou Y, Chen W et al (2025) Analysis and mining of brodalumab adverse events based on FAERS database [J]. Sci Rep 15(1):18175","journal-title":"Sci Rep"},{"issue":"1","key":"5895_CR78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cyto.2012.03.027","volume":"59","author":"XM Wang","year":"2012","unstructured":"Wang XM, Lehky TJ, Brell JM et al (2012) Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy [J]. Cytokine 59(1):3\u20139","journal-title":"Cytokine"},{"key":"5895_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-026-03178-2","author":"Y Xie","year":"2026","unstructured":"Xie Y, Luo Y, Chen Y et al (2026) Post-marketing safety profile of bictegravir\/emtricitabine\/tenofovir alafenamide: a FAERS pharmacovigilance study with EudraVigilance validation and mechanistic investigation of pancreatitis. Virol J. https:\/\/doi.org\/10.1186\/s12985-026-03178-2","journal-title":"Virol J"},{"issue":"W1","key":"5895_CR80","doi-asserted-by":"publisher","first-page":"W5","DOI":"10.1093\/nar\/gkab255","volume":"49","author":"G Xiong","year":"2021","unstructured":"Xiong G, Wu Z, Yi J et al (2021) ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties [J]. Nucleic Acids Res 49(W1):W5-w14","journal-title":"Nucleic Acids Res"},{"key":"5895_CR81","doi-asserted-by":"publisher","first-page":"1382441","DOI":"10.3389\/fphar.2024.1382441","volume":"15","author":"J Wu","year":"2024","unstructured":"Wu J, Pan H, Shen L et al (2024) Assessing the safety of bedaquiline: insight from adverse event reporting system analysis [J]. Front Pharmacol 15:1382441","journal-title":"Front Pharmacol"},{"issue":"11","key":"5895_CR82","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41596-024-01020-z","volume":"19","author":"S Xu","year":"2024","unstructured":"Xu S, Hu E, Cai Y et al (2024) Using clusterProfiler to characterize multiomics data [J]. Nat Protoc 19(11):3292\u20133320","journal-title":"Nat Protoc"},{"issue":"4","key":"5895_CR83","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1093\/rheumatology\/kead285","volume":"63","author":"S Yamaguchi","year":"2024","unstructured":"Yamaguchi S, Yamazaki M, Kido T et al (2024) A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan [J]. Rheumatology (Oxford) 63(4):e120\u2013e122","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5895_CR84","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/mrcr\/rxae071","volume":"9","author":"H Yamaguchi","year":"2025","unstructured":"Yamaguchi H, Fujii N, Shimizu H (2025) Persistent liver injury following avacopan discontinuation in antineutrophil cytoplasmic antibody-associated vasculitis: a rare case of liver biopsy in the chronic phase of liver injury [J]. Mod Rheumatol Case Rep 9(1):163\u2013167","journal-title":"Mod Rheumatol Case Rep"},{"issue":"15","key":"5895_CR85","doi-asserted-by":"publisher","first-page":"e42121","DOI":"10.1097\/MD.0000000000042121","volume":"104","author":"R Yamashita","year":"2025","unstructured":"Yamashita R, Izumi Y, Takane K et al (2025) Drug-induced liver injury due to avacopan improved by mycophenolate mofetil: a case report [J]. Medicine (Baltimore) 104(15):e42121","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"5895_CR86","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/nmeth.3484","volume":"12","author":"H Yang","year":"2015","unstructured":"Yang H, Robinson PN, Wang K (2015) Phenolyzer: phenotype-based prioritization of candidate genes for human diseases [J]. Nat Methods 12(9):841\u2013843","journal-title":"Nat Methods"},{"issue":"1","key":"5895_CR87","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation [J]. Pharmacol Ther 138(1):103\u2013141","journal-title":"Pharmacol Ther"},{"issue":"9","key":"5895_CR88","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/j.ekir.2024.07.007","volume":"9","author":"J Zimmermann","year":"2024","unstructured":"Zimmermann J, Sonnemann J, Jabs WJ et al (2024) Avacopan in anti-neutrophil cytoplasmic autoantibodies-associated vasculitis in a real-world setting [J]. Kidney Int Rep 9(9):2803\u20132808","journal-title":"Kidney Int Rep"},{"issue":"10","key":"5895_CR89","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/14740338.2024.2393268","volume":"24","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Sun S, Wang Y (2025) Adverse events associated with Atogepant: a FAERS-based pharmacovigilance analysis [J]. Expert Opin Drug Saf 24(10):1185\u20131191","journal-title":"Expert Opin Drug Saf"},{"key":"5895_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312808","author":"M Zhao","year":"2021","unstructured":"Zhao M, Ma J, Li M et al (2021) Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222312808","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5895_CR91","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","volume":"22","author":"J Zhou","year":"2024","unstructured":"Zhou J, Zheng Y, Xu B et al (2024) Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database [J]. BMC Med 22(1):65","journal-title":"BMC Med"},{"issue":"6","key":"5895_CR92","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ekir.2024.03.022","volume":"9","author":"R Zonozi","year":"2024","unstructured":"Zonozi R, Aqeel F, Le D et al (2024) Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis [J]. Kidney Int Rep 9(6):1783\u20131791","journal-title":"Kidney Int Rep"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05895-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05895-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05895-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:05:06Z","timestamp":1789027506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05895-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":92,"alternative-id":["5895"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05895-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study utilized publicly available, de-identified data from the FAERS, JADER, and EudraVigilance databases, and therefore, human ethical approval is not required according to the guidelines of the relevant institutions or countries. All the authors have read and agreed to the published version of the manuscript.","order":1,"name":"Ethics","label":"Human ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}